TET Medical, Inc.

TETmedical focuses on in vitro diagnostics, specializing in innovative solutions for stroke assessment. Their technology enhances the accuracy and speed of diagnostics through advanced nanomedicine. Founded in 2021 in Fair Haven, US, TET Medical, Inc. develops in vitro diagnostic tests.

The company has completed 1 deal with its most recent funding round occurring on May 31, 2023, raising USD 2. 462 mn in venture funding. TETmedical, Inc. specializes in innovative nanomedicine solutions, with its flagship product being the Neuron Specific Enolase Functional Activity Stroke Test (NSE-FAST).

This in vitro diagnostic test is designed to assess brain injury from stroke and is used in clinical settings, particularly within Emergency Departments. The NSE-FAST utilizes a patented TET nanobot technology that enables high-sensitivity detection of biomarkers such as proteins and enzymes, significantly enhancing diagnostic speed and accuracy compared to traditional antibody assays. TETmedical's technology is rooted in research from Cornell University, and the company aims to improve patient outcomes in critical healthcare settings. Their primary market includes hospitals and healthcare facilities in North America, especially those focusing on stroke management and neurological assessments.

TETmedical operates through a B2B model, primarily generating revenue from sales to hospitals and healthcare providers utilizing their NSE-FAST diagnostic tool. The company’s transactions typically involve direct sales to healthcare institutions, where the NSE-FAST is integrated into existing emergency care protocols. Pricing structures are established based on the clinical value offered by the NSE-FAST, including its high sensitivity and predictive capabilities. This model allows healthcare providers to efficiently rule out ischemic strokes, potentially lowering costs associated with unnecessary treatments and improving patient care standards.

The company is currently in clinical studies, and as such, specific pricing details for the NSE-FAST are not disclosed publicly. TET Medical, Inc. is focused on expanding its market presence and enhancing its product offerings. The company aims to release new products related to stroke diagnostics and improve existing technologies.

The recent funding of USD 2. 462 mn raised in May 2023 will support these initiatives as the company seeks to expand its reach into new healthcare markets in North America. Specific timelines for product launches and market expansions are yet to be detailed.